TSX open
Loading markets…

Advertisement

Stocks

Why Cipher Pharmaceuticals Inc stock is gaining today

By Wealth Awesome -

This move is archived. Current quotes and coverage live on the stock page.

Stocks & ETFs:CPH.TO

Get CPH alerts:

Photos provided by Pexels

Cipher Pharmaceuticals Inc is making waves on the TSX, with a notable gain of 1.51% in the last trading session.

Investors are taking notice as Cipher Pharmaceuticals Inc (CPH.TO) closed at CA$16.18, reflecting a positive sentiment in the market. This uptick comes amid a backdrop of robust financial performance and strategic initiatives that position the company favorably in the pharmaceutical sector.

Advertisement

Cipher Pharmaceuticals Inc

CPH.TO

Full stock page →

CPH.TO

Cipher Pharmaceuticals Inc

Source:WealthAwesomeWealthAwesome
$3.83 (-20.99%)
120 day period
$13.68$16.71$19.74Mar 31Jun 25Sep 21

Market cap

$372.84M

P/E

9.4x

52W high

$20.56

52W low

$12.48

1W change

-2.37%

Beta

0.40

Analyst Price Targets

Based on analyst covering CPH · as of Sep 17, 2026

📈

Wall Street analysts forecast CPH stock price to rise 38.3% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$19.95

+38.3% Upside

Current Price

C$14.42

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on CPH's historical volatility

HistoricalForecast68%95%
C$4.83C$9.88C$14.93C$19.98C$25.03C$30.08TodayMay 13Jul 17Sep 21Nov 3Dec 17Jan 29

30-Day Vol

74.0%

Annualized

90-Day Vol

46.4%

Annualized

Trend (90d)

-50.0%

Annualized drift

90d Mean

C$12.06

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$13.59C$10.53C$17.54
60 trading daysC$12.80C$8.92C$18.37
90 trading daysC$12.06C$7.75C$18.77

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: With a market cap of CA$411.6 million and a P/E ratio of 9.60, Cipher Pharmaceuticals is attracting attention from value investors looking for growth opportunities in the healthcare space.

1.51% Gain in One Day

Cipher Pharmaceuticals Inc saw a 1.51% increase in stock price, closing at CA$16.18, reflecting investor confidence.

Bull case

Cipher's recent financial results show impressive growth, with a 51% increase in revenue year-over-year. This suggests that the stock could keep climbing. The company's Normal Course Issuer Bid might also boost shareholder value by reducing the public float.

Bear case

Even with the positive movement, investors should stay cautious. The pharmaceutical sector can be unpredictable, and any future earnings reports that fall short of expectations could lead to a drop in stock performance.

Recent Performance Overview

Advertisement

In the last trading session, Cipher Pharmaceuticals Inc experienced a gain of 1.51%, closing at CA$16.18. This performance aligns with the company's recent financial successes, including record-high revenue and net income growth. Investors are optimistic about the company's trajectory, especially given its low P/E ratio of 9.60, suggesting it may be undervalued.

Financial Highlights

Cipher's financial results have been strong, with a 51% increase in revenue for the full year of 2025, reaching CA$50.5 million. The company reported a net income of CA$27.3 million, up 137% from the previous year, indicating strong operational efficiency and market demand for its products. This financial strength likely contributes to the recent stock price increase.

Looking Ahead

As Cipher Pharmaceuticals continues to execute its strategic initiatives, including its Normal Course Issuer Bid, investors should keep an eye on upcoming earnings reports. While the current gain is promising, the inherent risks in the pharmaceutical sector require a cautious approach to investment decisions.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: June 18, 2026
Last Updated: June 18, 2026
PARTNER SPOTLIGHT

Blue Cross Life® Term Life Insurance

Affordable term life coverage in Canada — get a free quote in seconds, no credit card required.

  • Coverage from $100,000 to $5 million, terms of 10–30 years
  • 10% off first-year premiums when couples apply together
  • Fully digital application — many qualify without a medical exam

Sponsored links

Advertisement